News from liposcience, inc

Jun 24, 2014, 08:00 ET

Study Published in Atherosclerosis Provides First Large-Scale, Real-World Evidence of Link Between Low LDL Particle Levels and Reduced Risk of Cardiovascular Disease

 LipoScience, Inc. (NASDAQ: LPDX), today announced the publication of the first large-scale real world study evidencing a link between low...

Jun 14, 2014, 13:00 ET

NMR-based Diabetes Risk Index (DRI) Helps to Identify Normal-weight Individuals at High Risk of Progressing to Type 2 Diabetes

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to...

May 02, 2014, 08:30 ET

Outcomes Study Supports Use of LDL Particle Number to Guide Statin Therapy in Patients at Elevated Cardiovascular Risk

LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to...

Mar 31, 2014, 09:30 ET

Patients Managed to Target LDL Particle Number Experience Fewer Cardiovascular Events Than Patients Managed to Target LDL Cholesterol, According to Study

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to...

Nov 25, 2013, 09:00 ET

LipoScience Announces Agreement With Scripps Health For First California Placement Of Vantera® Clinical Analyzer

 LipoScience, Inc. (NASDAQ:  LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR)...

Nov 18, 2013, 10:30 ET

Real-World Data Presented At AHA Scientific Sessions Demonstrate Relationship Between Low-Density Lipoprotein Particle (LDL-P) Number And Future Risk Of Coronary Heart Disease

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR)...

Sep 06, 2013, 09:00 ET

LipoScience Announces Appointment Of William Cromwell, M.D., As Chief Medical Officer

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of...

Sep 04, 2013, 09:52 ET

LipoScience Announces New Data Supporting High-Density Lipoprotein Particle (HDL-P) Number As Marker Of Cardiovascular Risk

 LipoScience, Inc., (NASDAQ: LPDX) a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR)...

Aug 09, 2013, 09:00 ET

LipoScience Announces Appointment Of Vice President, General Counsel And Corporate Secretary

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of...

Jul 31, 2013, 10:30 ET

LipoScience Research Sheds Light On Novel Markers Via Nuclear Magnetic Resonance (NMR) Spectroscopy

 Researchers from LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the...

Jul 29, 2013, 09:00 ET

LipoScience Announces Agreement With ARUP Clinical Laboratories For Placement Of Vantera® Clinical Analyzer

 LipoScience, Inc.,  (NASDAQ:  LPDX) a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR)...

Jul 12, 2013, 09:00 ET

American Association Of Clinical Endocrinologists (AACE) Endorses Measurement Of Low-Density Lipoprotein Particle (LDL-P) Number

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of...

Jun 23, 2013, 12:30 ET

LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting

LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to...

Jun 22, 2013, 13:30 ET

LipoScience Unveils Research Supporting NMR Diabetes Risk Test At The 2013 American Diabetes Association Scientific Sessions

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to...

Jun 19, 2013, 16:00 ET

Analysis Demonstrates Cost-Effectiveness Of Managing Low-Density Lipoprotein Particle Number To Reduce Cardiovascular Disease Risk

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to...

May 31, 2013, 15:30 ET

LipoScience Presents Data At The National Lipid Association Annual Scientific Sessions

 LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to...

May 22, 2013, 09:00 ET

LipoScience's Vantera® Clinical Analyzer To Provide Hospitals And Physicians With Lipoprotein Analysis For Cardiovascular Disease Management

 LipoScience, Inc.,  (NASDAQ:  LPDX) a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR)...

Jan 12, 2010, 09:04 ET
A F LIPOSCIENCE AND NOVANT HEART & WELLNESS OF RALEIGH NMR LIPOPROFI LIPOSCIENCE AND NOVANT HEART & WELLNESS OF RALEIGH NMR LIPOPROFILE TEST

Advanced but affordable diagnostic tests like the NMR LipoProfile test may help make 2010 a healthier year for many. (PRNewsFoto/LipoScience Inc. and Novant Heart & Wellness of Raleigh)[TK]
 RALEIGH, NC UNITED STATES
 01/11/2010

Making 2010 a Healthier Year for You: Novant Heart & Wellness Discusses Five Life-Changing Finds for Less than $100 Each

While affording quality health care may seem like an impossible feat at times, experts in cardiovascular health, exercise and family health, point...

Mar 28, 2008, 01:00 ET

LDL Particle Measurement by NMR Recognized in Consensus Statement by the American Diabetes Association and the American College of Cardiology

RALEIGH, N.C., March 28 /PRNewswire/ -- The American Diabetes Association (ADA) and the American College of Cardiology (ACC) issued a consensus...

Dec 13, 2007, 00:00 ET

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge